MariMed (MRMD) director receives 166,985 RSUs in lieu of cash board fees

Rhea-AI Filing Summary

MariMed Inc. director reports new stock-based compensation grant

A MariMed Inc. (MRMD) director filed a Form 4 disclosing an award of 166,985 restricted stock units (RSUs) on December 5, 2025. Each RSU converts into one share of MariMed common stock, and the award vests in full on December 15, 2025 under the terms of the award agreement. The RSUs were granted in lieu of cash for a portion of the director’s board fees, meaning the director chose to receive equity instead of part of the normal cash compensation. Following this grant, the director reports 315,686 shares of common stock held directly and 166,985 RSUs directly beneficially owned. This filing highlights ongoing use of equity-based compensation to align director pay with company performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Selhub Eva M.D.

(Last) (First) (Middle)

C/O MARIMED INC.

10 OCEANA WAY

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock								315,686	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSU)	(1)	12/05/2025		A		166,985		(2)	(2)	Common Stock, par value $.001 per share	166,985	$0	166,985	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. The RSUs vest in full on December 15, 2025, in accordance with the terms of the award agreement between the Issuer and the Reporting Person.

Remarks:

The RSUs were granted in lieu of cash as payment for a portion of the Reporting Person's fees for serving on the Issuer's Board of Directors.

	/s/ Eva Selhub	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MariMed (MRMD) report in this Form 4?

The filing reports that a MariMed director received 166,985 restricted stock units (RSUs) on December 5, 2025, as part of board compensation.

How do the MariMed (MRMD) RSUs reported in this filing work?

The 166,985 RSUs convert into MariMed common stock on a one-for-one basis, meaning each RSU becomes one share when it vests.

When do the RSUs granted to the MariMed (MRMD) director vest?

The reported RSUs vest in full on December 15, 2025, in accordance with the award agreement between MariMed and the director.

Why did the MariMed (MRMD) director receive RSUs instead of cash?

The RSUs were granted in lieu of cash as payment for a portion of the director’s fees for serving on MariMed’s Board of Directors.

How many MariMed (MRMD) shares does the director own after this transaction?

After the reported transaction, the director directly owns 315,686 shares of common stock and 166,985 RSUs, all reported as directly beneficially owned.

What is the exercise or purchase price of the RSUs reported for MariMed (MRMD)?

The filing lists the price of the 166,985 RSUs as $0, which is typical for restricted stock units granted as compensation.